Dexamethasone 0.7 mg · intravitreal implant
Injections & Implants, Steroid
Approved uses
Macular edema following branch or central retinal vein occlusion
One 0.7 mg implant intravitreally under aseptic conditions
Duration of effect is roughly 3 to 6 months, so repeat treatment is usual
Non-infectious uveitis affecting the posterior segment
One 0.7 mg implant intravitreally
Diabetic macular edema
One 0.7 mg implant intravitreally
Contraindications
- Active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, such as active epithelial herpes simplex keratitis, vaccinia and varicella, and mycobacterial and fungal infections
- Glaucoma with a cup-to-disc ratio greater than 0.8
- Torn or ruptured posterior lens capsule, because the implant may migrate into the anterior chamber; laser posterior capsulotomy in pseudophakic patients is not a contraindication
- Hypersensitivity to any component of the product
0.7 mg dexamethasone intravitreal implant in a foil pouch with one single-use applicator.
Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Warnings & Precautions
- Endophthalmitis and retinal detachment: intravitreal injection has been associated with endophthalmitis, eye inflammation, increased intraocular pressure and retinal detachment; monitor patients regularly following the injection.
- Cataract, glaucoma and ocular infection: corticosteroids may cause posterior subcapsular cataract, raised intraocular pressure and glaucoma, and may enhance secondary ocular infection by bacteria, fungi or viruses. They are not recommended in patients with a history of ocular herpes simplex, because the virus may reactivate.
- Migration into the anterior chamber: the implant may migrate into the anterior chamber in patients whose posterior lens capsule is torn or ruptured; laser posterior capsulotomy in pseudophakic patients is not a contraindication.
Common Side Effects
In controlled studies, the most common adverse reactions reported by 20-70% of patients were cataract, increased intraocular pressure and conjunctival hemorrhage.
Pregnancy: No adequate and well-controlled studies in pregnant women. Topical ocular dexamethasone in mice and rabbits during organogenesis produced cleft palate and embryofetal death in mice, and malformations of the abdominal wall/intestines and kidneys in rabbits, at doses 5 and 4 times higher than the recommended human ophthalmic dose.
Lactation: Systemically administered corticosteroids are present in human milk and can suppress growth and interfere with endogenous corticosteroid production. There is no information regarding the presence of dexamethasone in human milk, the effects on the breastfed infant, or the effects on milk production.
Safety and effectiveness of OZURDEX in pediatric patients have not been established.